Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Instagram Outage Disrupts Thousands of U.S. Users 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 31, 2017 -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, today announced that it will report financial results for the fiscal quarter and year ended June 30, 2017 before the market opens on Wednesday, September 13, 2017. AGTC management will host a conference call beginning at 8:00 am ET that day to review results and provide a corporate update.
AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC's pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia caused by mutations in the CNGB3 and CNGA3 genes, wet age-related macular degeneration and an optogenetics program.
To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The passcode is 13669175. A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events.cfm. Please log in approximately 10 minutes prior to the scheduled start time.
The archived webcast will be available in the Events and Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's product pipeline includes ophthalmology programs in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration, and an optogenetics program with Bionic Sight. AGTC's non-ophthalmology programs include adrenoleukodystrophy and an otology program, which is in pre-clinical development, and the company expects to advance several otology product candidates into clinical development in the next few years. Each of AGTC's XLRS, XLRP and adrenoleukodystrophy programs are part of its collaboration and license agreement with Biogen. AGTC employs a highly-targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need that it believes are clinically feasible and present commercial opportunities. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Tom Vickery (PR) Lazar Partners Ltd. T: (212) 867-1768 or (646) 871-8482 [email protected] or [email protected] CORPORATE CONTACTS: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
